- Home
- SHFS vs LPCN Comparison
SHFS vs LPCN Comparison
Compare SHFS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHFS
- LPCN
- Stock Information
- Founded
- SHFS 2015
- LPCN 1997
- Country
- SHFS United States
- LPCN United States
- Employees
- SHFS N/A
- LPCN N/A
- Industry
- SHFS Finance: Consumer Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- SHFS Finance
- LPCN Health Care
- Exchange
- SHFS Nasdaq
- LPCN Nasdaq
- Market Cap
- SHFS 20.8M
- LPCN 16.1M
- IPO Year
- SHFS N/A
- LPCN N/A
- Fundamental
- Price
- SHFS $2.17
- LPCN $3.25
- Analyst Decision
- SHFS
- LPCN Strong Buy
- Analyst Count
- SHFS 0
- LPCN 2
- Target Price
- SHFS N/A
- LPCN $9.00
- AVG Volume (30 Days)
- SHFS 9.5K
- LPCN 61.6K
- Earning Date
- SHFS 08-13-2025
- LPCN 08-07-2025
- Dividend Yield
- SHFS N/A
- LPCN N/A
- EPS Growth
- SHFS N/A
- LPCN N/A
- EPS
- SHFS N/A
- LPCN N/A
- Revenue
- SHFS $13,956,453.00
- LPCN $3,674,834.00
- Revenue This Year
- SHFS N/A
- LPCN N/A
- Revenue Next Year
- SHFS N/A
- LPCN N/A
- P/E Ratio
- SHFS N/A
- LPCN N/A
- Revenue Growth
- SHFS N/A
- LPCN N/A
- 52 Week Low
- SHFS $1.84
- LPCN $2.68
- 52 Week High
- SHFS $14.86
- LPCN $8.23
- Technical
- Relative Strength Index (RSI)
- SHFS 43.20
- LPCN 44.63
- Support Level
- SHFS $2.03
- LPCN $3.10
- Resistance Level
- SHFS $2.40
- LPCN $3.23
- Average True Range (ATR)
- SHFS 0.14
- LPCN 0.16
- MACD
- SHFS 0.01
- LPCN -0.00
- Stochastic Oscillator
- SHFS 42.47
- LPCN 19.76
About SHFS SHF Holdings Inc.
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring among others.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.